Mexico buys 35 million doses of Consino recombinant new crown vaccine in partnership with Phase III clinical trials.

It is reported that the Consino Biological Program for Mexico's Ministry of Health to provide a new crown vaccine to meet the local demand for new crown vaccination in Mexico.
Mexican company EPIC RESERCH S de RL de CV ("EPIC") will assist in the local clinical Phase III trial of the new crown vaccine.
, Mexico also purchased 39 million doses and 17 million doses of new crown vaccine from AstraZeneta and Pfizer, respectively.
Pfizer and Pfizer are expected to be available as early as December, and AstraZeneta's vaccine is expected to be available in March next year.
Pfizer, AstraZeneta and the International Alliance for Vaccines (Covax) require two doses of the vaccine, while the concino's vaccine requires only one dose.
the final cost of the three vaccines purchased from Mexico is estimated at about $1.7 billion.
Mexico's finance minister, Arturo Herrera, said the country had already made $159m in advance and would increase the advance to $321m by the end of the year.
vaccines will be made available to the public free of charge.
Mexican Foreign Minister Marcelo Ebrard said Mexico will participate in the third phase of clinical trials conducted by Concino Bio in a few days.
, with a population of 126 million, has one of the highest number of deaths from the new coronavirus, with nearly 84,000 so far.
public information shows that the recombination of the new crown vaccine (Ad5-nCoV) has been approved by the Russian and Pakistani Ministries of Health clinical trials, and respectively, in the local international Phase III clinical trials.
, the research and development team plans to actively communicate with several countries in West Asia, Latin America and other regions to promote international multi-center clinical trials.
(Photo: Baidu's new crown outbreak real-time data)